Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919808 | 1.00 | METAP1 (0.45) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL2696598 | 0.92 | GRM5 (0.46) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL27703346 | 0.90 | METAP1 (0.44) | METAP1NAMPTCYP17A1ATRKDM4E | |
| SCHEMBL2695265 | 0.89 | METAP1 (0.42) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL7410153 | 0.88 | METAP1 (0.41) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL16766552 | 0.87 | KDM4E (0.47) | METAP1NAMPTCYP17A1ATRKDM4E | |
| SCHEMBL30450099 | 0.86 | METAP1 (0.42) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL29952507 | 0.86 | METAP1 (0.42) | METAP1NAMPTCYP17A1ATRKDM4E | |
| SCHEMBL8609349 | 0.86 | METAP1 (0.42) | METAP1NAMPTMMECYP17A1ATR | |
| SCHEMBL2694492 | 0.86 | METAP1 (0.42) | METAP1NAMPTCYP17A1ATRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807251-B1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-07 | — | — | EP | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-31 | — | — | US | disclosed |
| WO-2019244000-A1 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| EP-0540143-B1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2003-02-05 | — | — | EP | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| CN-1069882-A | The Compounds and methods for that suppresses HIV and correlated virus | MEDIVIR AB (CH) | 1993-03-17 | — | — | CN | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | METAP1 4461/4885NAMPT 3171/4885MME 4700/4885 |
| US-11345666-B2 | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | RORC, RORB, RORA | METAP1 3740/4885NAMPT 1425/4885MME 4821/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | METAP1 3654/4885NAMPT 653/4885MME 4445/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | METAP1 4157/4885NAMPT 1050/4885MME 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.